Navigation Links
Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
Date:3/14/2011

ds' selectivity and specificity, leading to a potentially safer and more effective cancer treatment.

About Cornerstone Pharmaceuticals Cornerstone Pharmaceuticals, Inc. is a privately held company committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone currently has a drug in clinical trials targeting enzymes crucial to cancer cell metabolism.  AEMD compounds, the company's unique approach to cancer treatment, is the leading platform in cancer metabolism.  It has facilitated the discovery of first-in-class drugs and a novel drug delivery technology - both with the potential to transform the way cancer is treated.

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whe
'/>"/>

SOURCE Cornerstone Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
2. Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call
3. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
4. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
5. Cornerstone Therapeutics Announces Collaboration with The Cough Company
6. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
7. Cornerstone Therapeutics Announces Management Change
8. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
9. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
10. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
11. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Cephasonics, a ... today announced the introduction of the cQuest ... network-based communications with all cQuest Ultrasound™ hardware ... technology, including this new capability, at Hospitalar ... Brazil from May 21-24.  Cephasonics ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:5/21/2013)... Long Beach, CA (PRWEB) May 21, 2013 ... the 3rd Annual EB-5 Investment Summit: Dealmakers Conference ... The Dealmakers Conference will focus on exploring alternative ... will provide the latest market, legal and economic ... executives, immigration and legal professionals within the EB-5 ...
(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The ... on cable networks and cable channels across the country, ... on its YouTube channel. The producers of the series ... in the shipping industry, the manufacturing industry, health-related companies, ... medical facilities and medical practitioners in all parts of ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving ... residents in the Creative Corridor region, is releasing results ... news conference on Thursday, May 23rd at 10:30 a.m. ... 2008. , The survey is a critical ... efforts that attract, nurture and retain people of diverse ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... Recognize Efforts to Safeguard Sight, Promote Healthy Vision ... for Children and Expand Access to ... was recognized for providing important leadership on health care,policy issues ... the 34,000 member American Optometric Association (AOA).,Optometrists in West Virginia ...
... Will Follow 60,000 Women for 5 Years, ... aged 55,years and older have enrolled in a ... of osteoporosis across the globe. Launch of the,Global ... announced,today at ECCEO 8 (Eighth European Congress on ...
... at Tri-City Medical Center (TCMC) achieved union recognition,Wednesday ... Service,confirmed that caregivers strongly supported unionization and had ... TCMC caregivers become members of SEIU United Healthcare ... workers who have achieved industry a,voice on the ...
... month of tough breathing may help asthma sufferers breathe easier ... of Houston professor. , In a move that ... Oath first do no harm Richard Bond, associate ... medical taboo to treat asthma. Although counterintuitive, Bonds studies ...
... under control , , WEDNESDAY, April 9 (HealthDay News) -- In ... swept across eight Midwestern states, but a new study claims ... outbreak was limited, because the number of people in the ... high, explained study co-author Amy A. Parker, from the ...
... Mr. Muneo Takashi has been,named to head ... Organization,(JETRO Chicago). As the new Chief Executive Director, ... completing his assignment in Chicago., As Chief ... in its activities designed to facilitate business development,between ...
Cached Medicine News:Health News:Sen. Robert Byrd Receives AOA Health Care Leadership Award 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 2Health News:Landmark Study Aims to Improve Osteoporosis Care Standards Worldwide 3Health News:North County Caregivers Join United Healthcare Workers 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 2Health News:First do no harm? UH prof taking opposite approach to treat asthma 3Health News:First do no harm? UH prof taking opposite approach to treat asthma 4Health News:Mumps Outbreak in Midwest Could Have Been Worse 2Health News:Mumps Outbreak in Midwest Could Have Been Worse 3Health News:Muneo Takashi Named Chief Executive Director of Japan's Midwest Trade Office 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: